FROM THE DESK OF THE GROUP EDITOR-IN-CHIE

KK Aggarwal

English

Asian Journal Of Diabetology

5Asian Journal of Diabetology, Vol. 22, No. 1, January - March 2021FROM THE DESK OF THE GROUP EDITOR-IN-CHIEFCMAAO Coronavirus Facts and Myth Buster: Around the GlobeNational Comprehensive Cancer Network (NCCN) – Preliminary Recommendations for COVID-19 Vaccination in Patients with CancerPatients receiving hematopoietic cell transplantation or cellular therapy: Coronavirus disease 2019 (COVID-19) vaccination should be done ≥3 months after hematopoietic cell transplantation (allogeneic or autologous) or cellular therapy (e.g., chimeric antigen receptor [CAR] T-cell therapy).Patients with hematologic malignancies: For patients receiving intensive cytotoxic chemotherapy, vaccination against COVID-19 must be delayed until the absolute neutrophil count has recovered. For patients with marrow failure due to disease or treatment who are Dr KK AggarwalPresident, CMAAO and HCFIPast National President, IMAGroup Editor-in-Chief, IJCP Grouplikely to have limited or no recovery, and for those on long-term maintenance therapy, vaccination should be done when the vaccine becomes available.Patients with solid-tumor malignancies: For patients who are receiving cytotoxic chemotherapy, targeted therapy, checkpoint inhibitor therapy or other immunotherapy, or radiation therapy, vaccination should be done when the vaccine becomes available.For patients who have to undergo a major surgery, COVID-19 vaccination must be postponed until at least a few days after surgery.(Excerpts from Medscape) With input from Dr Monica Vasudev

CMAAO Coronavirus Facts and Myth Buster: Around the Globe

https://ojs.ijcp.in/AJD/article/download/69/61

CMAAO Coronavirus Facts and Myth Buster: Around the Globe

Abstract

Similar works

Full text

Available Versions

Asian Journal Of Diabetology